NEW YORK, April 29 - Hybrigenics has acquired Dutch oncology target discovery company Semania, the companies said today.
The acquisition, in which Hybrigenics purchased 100 percent of Semaia's shares, enables Hybrigenics access to Semaia's oncology targets. These include therapeutic targets, both enzymes and cell surface proteins, in the Wnt pathway of colorectal cancer, and in the Ras-Raf and PKB/AKT pathways in other cancers.
Hybrigenics, of Paris, will use its yeast-two hybrid proteomics technology to explore the function of Semaia's targets and identify proteins that interact with these targets, the company said.
The company also said it expects the acquisition to "reinforce the international collaborations" it has with research institutes. Semaia, of Utrecht, was co-founded by Professors Hans Bos and Hans Clevers of the University of Utrecht.
In the acquisition, Semiaia CEO Rian De Jonge will become Hybrigenics' executive vice president of R&D, and Bos and Clevers will join Hybrigenics' scientific advisory board.
Hybrigenics currently has drug discovery programs in cancer and in infectious diseases including HIV and Hepatitis C.